Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Precemtabart tocentecan · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1: Precemtabart tocentecan (Precem-TcT) Monotherapy | EXPERIMENTAL | - |
| Arm 2: Precem-TcT plus Bevacizumab | EXPERIMENTAL | - |
| Arm 3: Trifluridine/Tipiracil (FTD-TPI) plus Bevacizumab | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Precemtabart tocentecan | DRUG | Precem-TcT, administered, once every 3 weeks intravenously, on Day 1 of each 21-day cycle. |
| Bevacizumab | DRUG | Bevacizumab, administered intravenously every 3 weeks on Day 1 of each 21-day cycle or every 2 weeks on Day 1 and Day 15 of each 28-day cycle. |
| Trifluridine/Tipiracil (FTD-TPI) | DRUG | FTD-TPI, tablet, administered orally twice daily, on Days 1 to 5 and Days 8 to 12 of each 28-day cycle. |
Inclusion Criteria: * Participants with documented histopathological diagnosis of metastatic colorectal cancer, who were intolerant to, or whose disease was refractory to, or progressed after standard systemic therapies and no more than 2 previous systemic treatment regimens in the metastatic setti...
Top 20 of 77 competitors
Precemtabart tocentecan is an investigational small molecule being studied for the treatment of metastatic colorectal cancer. It is currently in Phase 3 clinical development, specifically for patients with previously treated metastatic colorectal cancer. The drug is being evaluated in combination with or without bevacizumab compared to trifluridine/tipiracil plus bevacizumab.
Precemtabart tocentecan is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting a Phase 3 clinical trial for this drug in patients with metastatic colorectal cancer.
Precemtabart tocentecan is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 3 trial is actively recruiting participants with previously treated metastatic colorectal cancer.
Precemtabart tocentecan is being studied in a Phase 3 trial with the identifier NCT07549412. The trial is titled 'A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)'. It is actively recruiting and aims to enroll 1020 participants across multiple countries.
Yes, Precemtabart tocentecan is being evaluated in a randomized, active-controlled Phase 3 clinical trial. The study compares Precemtabart tocentecan with or without bevacizumab against trifluridine/tipiracil plus bevacizumab in patients with previously treated metastatic colorectal cancer.
The Phase 3 clinical trial for Precemtabart tocentecan is being conducted in multiple countries, including the United States, Australia, Canada, China, Japan, South Korea, and Taiwan. The trial is open to adults aged 18 years and older of all sexes.